- Home
- HBANZ vs ERNAW Comparison
HBANZ vs ERNAW Comparison
Compare HBANZ & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HBANZ
Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/1000th Interest in a Share of 5.50% Series L Non-Cumulative Perpetual Preferred Stock
Company Overview
Basic Information| Metric | HBANZ | ERNAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HBANZ | ERNAW |
|---|---|---|
| Price | $19.19 | $0.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.5K | ★ 31.2K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.93 | ★ 31.29 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,562,000,000.00 | $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $76.46 | ★ N/A |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $18.90 | $0.02 |
| 52 Week High | $22.23 | $0.23 |
Technical Indicators
Market Signals| Indicator | HBANZ | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 40.97 |
| Support Level | $19.12 | $0.03 |
| Resistance Level | $19.42 | $0.08 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 49.98 | 0.66 |
Price Performance
Historical ComparisonAbout HBANZ Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/1000th Interest in a Share of 5.50% Series L Non-Cumulative Perpetual Preferred Stock
Huntington is a regional US bank with over $285 billion in assets. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About ERNAW Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.